Share Price and Basic Stock Data
Last Updated: June 14, 2025, 2:22 am
| PEG Ratio | 0.30 |
|---|
Competitors of Orchid Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 101 | 247/84.3 | 27.6 | 41.7 | 0.00 % | 12.9 % | 9.75 % | 10.0 |
| MPS Pharmaa Ltd | 5.27 Cr. | 2.76 | 4.33/2.50 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 41.6 Cr. | 56.0 | 94.9/44.5 | 8.73 | 0.00 % | 41.5 % | 14.4 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.1 Cr. | 21.9 | 29.1/13.1 | 31.4 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,974.12 Cr | 1,189.16 | 92.21 | 194.72 | 0.31% | 16.67% | 15.20% | 6.18 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 178 | 131 | 165 | 160 | 210 | 183 | 199 | 221 | 217 | 244 | 223 | 217 | 237 |
| Expenses | 152 | 119 | 147 | 146 | 170 | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 209 |
| Operating Profit | 26 | 12 | 18 | 14 | 40 | 22 | 23 | 35 | 29 | 32 | 30 | 26 | 28 |
| OPM % | 14% | 10% | 11% | 9% | 19% | 12% | 12% | 16% | 13% | 13% | 14% | 12% | 12% |
| Other Income | -0 | 3 | 6 | 9 | 34 | 2 | 8 | 8 | 13 | 8 | 8 | 8 | 4 |
| Interest | 4 | 8 | 9 | 8 | 7 | 6 | 4 | 4 | 3 | 4 | 3 | 4 | 4 |
| Depreciation | 27 | 22 | 18 | 8 | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 |
| Profit before tax | -5 | -14 | -3 | 7 | 59 | 11 | 20 | 30 | 30 | 28 | 26 | 22 | 19 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -10% | -1% | 0% | 0% | -0% |
| Net Profit | -7 | -15 | -5 | 8 | 59 | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 |
| EPS in Rs | -1.61 | -3.68 | -1.32 | 1.86 | 14.49 | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 |
Last Updated: May 31, 2025, 8:14 am
Below is a detailed analysis of the quarterly data for Orchid Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 237.00 Cr.. The value appears strong and on an upward trend. It has increased from 217.00 Cr. (Dec 2024) to 237.00 Cr., marking an increase of 20.00 Cr..
- For Expenses, as of Mar 2025, the value is 209.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 191.00 Cr. (Dec 2024) to 209.00 Cr., marking an increase of 18.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Dec 2024) to 28.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Mar 2025, the value is 12.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 12.00%.
- For Other Income, as of Mar 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Dec 2024) to 4.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 4.00 Cr..
- For Depreciation, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 9.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Dec 2024) to 19.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
- For Net Profit, as of Mar 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Dec 2024) to 22.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 4.39. The value appears strong and on an upward trend. It has increased from 4.10 (Dec 2024) to 4.39, marking an increase of 0.29.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 3:18 pm
| Metric | Mar 2012 | Sep 2013n n 18m | Mar 2015n n 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,874 | 1,948 | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 902 |
| Expenses | 1,517 | 1,837 | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 783 |
| Operating Profit | 357 | 110 | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 118 |
| OPM % | 19% | 6% | 18% | 20% | 0% | 4% | -2% | -6% | 7% | 10% | 13% | 14% | 13% |
| Other Income | 52 | 92 | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 37 |
| Interest | 180 | 523 | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 14 |
| Depreciation | 154 | 252 | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 34 |
| Profit before tax | 75 | -573 | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 107 |
| Tax % | -29% | -2% | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | |
| Net Profit | 97 | -560 | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 110 |
| EPS in Rs | 13.84 | -79.21 | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 21.76 |
| Dividend Payout % | 22% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -77.42% | 28.69% | 119.55% | -289.86% | 10.69% | 98.29% | 2400.00% | 100.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 106.11% | 90.86% | -409.40% | 300.54% | 87.60% | 2301.71% | -2300.00% |
Orchid Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 14% |
| 3 Years: | 18% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 23% |
| 3 Years: | 249% |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | % |
| 3 Years: | 35% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: Unknown
Balance Sheet
Last Updated: June 12, 2025, 2:58 pm
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 |
| Reserves | 310 | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,217 |
| Borrowings | 3,204 | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 175 |
| Other Liabilities | 1,067 | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 246 |
| Total Liabilities | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
| Fixed Assets | 2,584 | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 649 |
| CWIP | 360 | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 64 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 50 |
| Other Assets | 1,706 | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 |
| Total Assets | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
Below is a detailed analysis of the balance sheet data for Orchid Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 51.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,217.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,119.00 Cr. (Mar 2024) to 1,217.00 Cr., marking an increase of 98.00 Cr..
- For Borrowings, as of Mar 2025, the value is 175.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 135.00 Cr. (Mar 2024) to 175.00 Cr., marking an increase of 40.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 246.00 Cr.. The value appears to be improving (decreasing). It has decreased from 249.00 Cr. (Mar 2024) to 246.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,688.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,554.00 Cr. (Mar 2024) to 1,688.00 Cr., marking an increase of 134.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 649.00 Cr.. The value appears strong and on an upward trend. It has increased from 620.00 Cr. (Mar 2024) to 649.00 Cr., marking an increase of 29.00 Cr..
- For CWIP, as of Mar 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Mar 2024) to 64.00 Cr., marking an increase of 33.00 Cr..
- For Investments, as of Mar 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2024) to 50.00 Cr., marking an increase of 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 925.00 Cr.. The value appears strong and on an upward trend. It has increased from 857.00 Cr. (Mar 2024) to 925.00 Cr., marking an increase of 68.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,688.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,554.00 Cr. (Mar 2024) to 1,688.00 Cr., marking an increase of 134.00 Cr..
Notably, the Reserves (1,217.00 Cr.) exceed the Borrowings (175.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2012 | Mar 2015n n 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2013n n 18m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 357.00 | 317.00 | 168.00 | 0.00 | 21.00 | -15.00 | -597.00 | -424.00 | -213.00 | -247.00 | -24.00 | 110.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 22 | 34 | 54 | 130 | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 |
| Inventory Days | 279 | 187 | 118 | 220 | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 |
| Days Payable | 186 | 220 | 146 | 341 | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 |
| Cash Conversion Cycle | 114 | -0 | 26 | 9 | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 |
| Working Capital Days | 34 | -113 | 86 | 97 | -226 | -505 | -735 | 166 | 305 | 136 | 154 | 124 |
| ROCE % | 8% | -3% | 1% | 1% | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 1,534,919 | 0.78 | 87.28 | 1,534,919 | 2025-04-22 17:25:24 | 0% |
| Quant Multi Asset Fund | 1,262,596 | 6.23 | 71.8 | 1,262,596 | 2025-04-22 17:25:24 | 0% |
| Nippon India Pharma Fund | 1,000,000 | 0.92 | 56.87 | 1,000,000 | 2025-04-22 17:25:24 | 0% |
| Quant Value Fund | 668,432 | 4.29 | 38.01 | 668,432 | 2025-04-22 17:25:24 | 0% |
| UTI Small Cap Fund | 445,000 | 0.73 | 25.3 | 445,000 | 2025-04-22 17:25:24 | 0% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 269,667 | 0.47 | 15.33 | 269,667 | 2025-04-22 17:25:24 | 0% |
| Tata Multi Asset Opportunities Fund | 175,260 | 0.48 | 9.97 | 175,260 | 2025-04-22 17:25:24 | 0% |
| Tata India Pharma & HealthCare Fund | 175,000 | 1.32 | 9.95 | 175,000 | 2025-04-22 17:25:24 | 0% |
| UTI Healthcare Fund | 100,000 | 0.67 | 5.69 | 100,000 | 2025-04-22 17:25:24 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.06 | 11.35 | -0.48 | -28.55 | -14.75 |
| Diluted EPS (Rs.) | 19.06 | 11.35 | -0.48 | -28.55 | -14.75 |
| Cash EPS (Rs.) | 25.30 | 25.30 | 21.71 | -1.87 | -1.26 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 230.58 | 168.72 | 158.61 | 159.96 | 250.97 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 230.58 | 168.72 | 158.61 | 159.96 | 250.97 |
| Revenue From Operations / Share (Rs.) | 161.55 | 163.14 | 137.09 | 110.26 | 124.47 |
| PBDIT / Share (Rs.) | 27.91 | 25.25 | 15.22 | 15.93 | -0.24 |
| PBIT / Share (Rs.) | 21.35 | 11.82 | -6.10 | -10.76 | -31.09 |
| PBT / Share (Rs.) | 18.13 | 13.54 | -13.94 | -23.34 | -32.11 |
| Net Profit / Share (Rs.) | 18.74 | 11.88 | 0.38 | -28.55 | -32.11 |
| NP After MI And SOA / Share (Rs.) | 18.17 | 11.35 | -0.47 | -28.55 | -32.11 |
| PBDIT Margin (%) | 17.27 | 15.47 | 11.10 | 14.44 | -0.19 |
| PBIT Margin (%) | 13.21 | 7.24 | -4.44 | -9.75 | -24.98 |
| PBT Margin (%) | 11.22 | 8.29 | -10.16 | -21.16 | -25.79 |
| Net Profit Margin (%) | 11.60 | 7.27 | 0.28 | -25.89 | -25.79 |
| NP After MI And SOA Margin (%) | 11.24 | 6.95 | -0.34 | -25.89 | -25.79 |
| Return on Networth / Equity (%) | 7.88 | 6.72 | -0.30 | -17.84 | -12.79 |
| Return on Capital Employeed (%) | 8.37 | 5.65 | -2.86 | -4.00 | -8.23 |
| Return On Assets (%) | 5.93 | 3.78 | -0.17 | -9.41 | -7.61 |
| Long Term Debt / Equity (X) | 0.10 | 0.21 | 0.32 | 0.65 | 0.48 |
| Total Debt / Equity (X) | 0.11 | 0.48 | 0.41 | 0.65 | 0.48 |
| Asset Turnover Ratio (%) | 0.58 | 0.57 | 0.47 | 0.30 | 0.21 |
| Current Ratio (X) | 3.04 | 1.35 | 1.87 | 3.87 | 3.25 |
| Quick Ratio (X) | 2.03 | 0.73 | 1.15 | 2.79 | 2.39 |
| Inventory Turnover Ratio (X) | 2.14 | 2.02 | 2.09 | 1.60 | 1.44 |
| Interest Coverage Ratio (X) | 8.65 | 3.20 | 1.94 | 1.27 | -0.23 |
| Interest Coverage Ratio (Post Tax) (X) | 6.81 | 1.50 | -0.77 | -0.85 | -30.52 |
| Enterprise Value (Cr.) | 5169.07 | 1869.70 | 1420.30 | 10472.28 | 346.98 |
| EV / Net Operating Revenue (X) | 6.31 | 2.81 | 2.54 | 23.27 | 0.68 |
| EV / EBITDA (X) | 36.52 | 18.14 | 22.86 | 161.10 | -350.31 |
| MarketCap / Net Operating Revenue (X) | 6.47 | 2.36 | 2.07 | 22.36 | 0.04 |
| Price / BV (X) | 4.53 | 2.28 | 1.79 | 15.41 | 0.02 |
| Price / Net Operating Revenue (X) | 6.47 | 2.36 | 2.07 | 22.36 | 0.04 |
| EarningsYield | 0.01 | 0.02 | 0.00 | -0.01 | -6.12 |
After reviewing the key financial ratios for Orchid Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 19.06. This value is within the healthy range. It has increased from 11.35 (Mar 23) to 19.06, marking an increase of 7.71.
- For Diluted EPS (Rs.), as of Mar 24, the value is 19.06. This value is within the healthy range. It has increased from 11.35 (Mar 23) to 19.06, marking an increase of 7.71.
- For Cash EPS (Rs.), as of Mar 24, the value is 25.30. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 25.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 230.58. It has increased from 168.72 (Mar 23) to 230.58, marking an increase of 61.86.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 230.58. It has increased from 168.72 (Mar 23) to 230.58, marking an increase of 61.86.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 161.55. It has decreased from 163.14 (Mar 23) to 161.55, marking a decrease of 1.59.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 27.91. This value is within the healthy range. It has increased from 25.25 (Mar 23) to 27.91, marking an increase of 2.66.
- For PBIT / Share (Rs.), as of Mar 24, the value is 21.35. This value is within the healthy range. It has increased from 11.82 (Mar 23) to 21.35, marking an increase of 9.53.
- For PBT / Share (Rs.), as of Mar 24, the value is 18.13. This value is within the healthy range. It has increased from 13.54 (Mar 23) to 18.13, marking an increase of 4.59.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 18.74. This value is within the healthy range. It has increased from 11.88 (Mar 23) to 18.74, marking an increase of 6.86.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 18.17. This value is within the healthy range. It has increased from 11.35 (Mar 23) to 18.17, marking an increase of 6.82.
- For PBDIT Margin (%), as of Mar 24, the value is 17.27. This value is within the healthy range. It has increased from 15.47 (Mar 23) to 17.27, marking an increase of 1.80.
- For PBIT Margin (%), as of Mar 24, the value is 13.21. This value is within the healthy range. It has increased from 7.24 (Mar 23) to 13.21, marking an increase of 5.97.
- For PBT Margin (%), as of Mar 24, the value is 11.22. This value is within the healthy range. It has increased from 8.29 (Mar 23) to 11.22, marking an increase of 2.93.
- For Net Profit Margin (%), as of Mar 24, the value is 11.60. This value exceeds the healthy maximum of 10. It has increased from 7.27 (Mar 23) to 11.60, marking an increase of 4.33.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 11.24. This value is within the healthy range. It has increased from 6.95 (Mar 23) to 11.24, marking an increase of 4.29.
- For Return on Networth / Equity (%), as of Mar 24, the value is 7.88. This value is below the healthy minimum of 15. It has increased from 6.72 (Mar 23) to 7.88, marking an increase of 1.16.
- For Return on Capital Employeed (%), as of Mar 24, the value is 8.37. This value is below the healthy minimum of 10. It has increased from 5.65 (Mar 23) to 8.37, marking an increase of 2.72.
- For Return On Assets (%), as of Mar 24, the value is 5.93. This value is within the healthy range. It has increased from 3.78 (Mar 23) to 5.93, marking an increase of 2.15.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 0.2. It has decreased from 0.21 (Mar 23) to 0.10, marking a decrease of 0.11.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.11. This value is within the healthy range. It has decreased from 0.48 (Mar 23) to 0.11, marking a decrease of 0.37.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.58. It has increased from 0.57 (Mar 23) to 0.58, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 24, the value is 3.04. This value exceeds the healthy maximum of 3. It has increased from 1.35 (Mar 23) to 3.04, marking an increase of 1.69.
- For Quick Ratio (X), as of Mar 24, the value is 2.03. This value exceeds the healthy maximum of 2. It has increased from 0.73 (Mar 23) to 2.03, marking an increase of 1.30.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.14. This value is below the healthy minimum of 4. It has increased from 2.02 (Mar 23) to 2.14, marking an increase of 0.12.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 8.65. This value is within the healthy range. It has increased from 3.20 (Mar 23) to 8.65, marking an increase of 5.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 6.81. This value is within the healthy range. It has increased from 1.50 (Mar 23) to 6.81, marking an increase of 5.31.
- For Enterprise Value (Cr.), as of Mar 24, the value is 5,169.07. It has increased from 1,869.70 (Mar 23) to 5,169.07, marking an increase of 3,299.37.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 6.31. This value exceeds the healthy maximum of 3. It has increased from 2.81 (Mar 23) to 6.31, marking an increase of 3.50.
- For EV / EBITDA (X), as of Mar 24, the value is 36.52. This value exceeds the healthy maximum of 15. It has increased from 18.14 (Mar 23) to 36.52, marking an increase of 18.38.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 6.47. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 23) to 6.47, marking an increase of 4.11.
- For Price / BV (X), as of Mar 24, the value is 4.53. This value exceeds the healthy maximum of 3. It has increased from 2.28 (Mar 23) to 4.53, marking an increase of 2.25.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 6.47. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 23) to 6.47, marking an increase of 4.11.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Orchid Pharma Ltd:
- Net Profit Margin: 11.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.37% (Industry Average ROCE: 16.53%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.88% (Industry Average ROE: 14.7%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.03
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.3 (Industry average Stock P/E: 77.1)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.11
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.6%
About the Company - Qualitative Analysis
Orchid Pharma Ltd. is a Public Limited Listed company incorporated on 01/07/1992 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24222TN1992PLC022994 and registration number is 022994. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 921.93 Cr. and Equity Capital is Rs. 50.72 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Tamil Nadu 600110 | corporate@orchidpharma.com http://www.orchidpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ram Gopal Agarwal | Chairman & Non-Exe.Director |
| Mr. Manish Dhanuka | Managing Director |
| Mr. Mridul Dhanuka | Whole Time Director |
| Mrs. Tanu Singla | Independent Director |
| Dr. Dharam Vir | Independent Director |
| Mr. Manoj Kumar Goyal | Independent Director |
| Mr. Mudit Tandon | Independent Director |
FAQ
What is the intrinsic value of Orchid Pharma Ltd?
Orchid Pharma Ltd's intrinsic value (as of 13 June 2025) is ₹605.75 — 15.16% lower the current market price of 714.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,614 Cr. market cap, FY2025-2026 high/low of ₹1,998/604, reserves of 1,217 Cr, and liabilities of 1,688 Cr.
What is the Market Cap of Orchid Pharma Ltd?
The Market Cap of Orchid Pharma Ltd is 3,614 Cr..
What is the current Stock Price of Orchid Pharma Ltd as on 13 June 2025?
The current stock price of Orchid Pharma Ltd as on 13 June 2025 is 714.
What is the High / Low of Orchid Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Orchid Pharma Ltd stocks is ₹1,998/604.
What is the Stock P/E of Orchid Pharma Ltd?
The Stock P/E of Orchid Pharma Ltd is 36.3.
What is the Book Value of Orchid Pharma Ltd?
The Book Value of Orchid Pharma Ltd is 250.
What is the Dividend Yield of Orchid Pharma Ltd?
The Dividend Yield of Orchid Pharma Ltd is 0.00 %.
What is the ROCE of Orchid Pharma Ltd?
The ROCE of Orchid Pharma Ltd is 8.02 %.
What is the ROE of Orchid Pharma Ltd?
The ROE of Orchid Pharma Ltd is 8.18 %.
What is the Face Value of Orchid Pharma Ltd?
The Face Value of Orchid Pharma Ltd is 10.0.